E-GEOD-50827 - ICGC Pancreas: Genomewide DNA methylation patterns in pancreatic ductal adenocarcinoma (gene expression of 103 samples)

Status
Released on 5 May 2014, last updated on 3 June 2014
Organism
Homo sapiens
Samples (103)
Array (1)
Protocols (7)
Description
Epigenetic modifications, particularly DNA methylation have been increasingly implicated in cancer. Although some genes display aberrant methylation in pancreatic cancer, a comprehensive global analysis is yet to be performed. To define the genome-wide pattern of DNA methylation in pancreatic ductal adenocarcinomas (PDAC), the methylation profile of 156 PDAC and 23 non-malignant pancreas was captured using high-density arrays. More than 90,000 CpG sites were significantly differentially methylated (DM) in PDAC relative to non-malignant pancreas, with pronounced alterations in a sub-set of 13,517 CpG sites. This sub-set of differentially methylated CpG sites segregated PDAC from non-malignant pancreas, regardless of tumour cellularity. As expected, PDAC hyper-methylation was most prevalent in the 5’ region of genes (including the proximal promoter, 5’UTR and CpG islands). From 3981 genes aberrantly methylated, approximately 36% showed significant correlation between methylation and mRNA expression levels. Pathway analysis revealed an enrichment of aberrant methylation in genes involved in key molecular mechanisms important to PDAC: TGF-β, WNT, Integrin signaling, Cell adhesion, Stellate cell activation and Axon guidance. Bisulfite amplicon deep sequencing and qRT-PCR expression analyses of axon guidance pathway genes SLIT2, SLIT3, ROBO1, ROBO3, SRGAP1, and MET suggested epigenetic suppression of SLIT-ROBO signaling and up-regulation of MET expression. Hypo-methylation of MET and ITGA2 correlated with high gene expression, which correlated with poor survival of PDAC patients. These data suggest that aberrant methylation plays an important role in pancreatic carcinogenesis affecting known core signaling pathways with important implications for disease pathophysiology and therapy. This dataset includes gene expression data from 103 primary tumour samples. 86 samples from this dataset have already been deposited into GEO (GSE36924), and has been duplicated here since the data has been processed differently. This data is also available through the International Cancer Genome Consortium (ICGC) Data Portal (http://dcc/icgc.org), under the project code: Pancreatic Cancer (QCMG, AU). Access to the restricted clinical data must be made through the ICGC Data Access Compliance Office (http://www.icgc.org/daco). This dataset contains gene expression array data from 103 primary pancreatic ductal adenocarcinoma samples. All samples have 1 biological replicate. These data have corresponding methylation 450K array data (GSE49149).
Experiment type
transcription profiling by array 
Contacts
Aldo Scarpa, Amber Johns, Andrew V Biankin, Angelika Christ, Ann-Marie Patch, Anthony J Gill, Clare Watson, Conrad Leonard, Craig Nourse, Darrin Taylor, David K Chang, David Miller, David Wood, Ilse Rooman, Jianmin Wu, John V Pearson, Karin S Kassahn, Katia Nones, Marc Jones, Marina Pajic, Mark J Cowley, Mark Pinese, Michelle Thomas, Nic Waddell, Peter Bailey, Rita T Lawlor, Sarah Song, Sean M Grimmond, Suzanne Manning
MIAME
PlatformsProtocolsFactorsProcessedRaw
Files
Investigation descriptionE-GEOD-50827.idf.txt
Sample and data relationshipE-GEOD-50827.sdrf.txt
Processed data (1)E-GEOD-50827.processed.1.zip
Array designA-GEOD-10558.adf.txt
Links